Proteolysis-Targeting Chimera against BCL-XL Inhibits Breast Cancer Metastasis
Project Number – R01 CA260239
Source – NIH/NCI
April 1, 2021 – March 31, 2026
In collaboration with Drs. Weizhou Zhang and Daohong Zhou
Selecting a Drug Development Candidate for Cancer Treatment
Source – Dialectic Therapeutics
April 1, 2021 – March 31, 2022
In collaboration with Dr. Daohong Zhou
Developing a Novel PROTAC-Based NR4A1 Degrader for Breast-Cancer Therapy
Project Number: BC200100P1 | Source: US Army Med Res Acquisition
January 1, 2021 – December 31, 2023
Partnering with Dr. Weizhou Zhang
Validating NR4A1 as a cancer target
Source: Sanofi, Inc
January 1, 2021 – December 31, 2021
In collaboration with Dr. Weizhou Zhang
Identifying Novel Senolytic Agents and Molecular Targets
Project Number: R56 AG065635 | Source: NIH/NIA
September 1, 2020 – August 31, 2021
In collaboration with Dr. Daohong Zhou
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes
Project Number: U19 AI150574 | Source: NIH/NIAID
June 16, 2020 – May 31, 2025
In collaboration with Dr. Daohong Zhou
Inhibition of Bcl-xL by Targeted Degradation
Project Number: R01 CA241191 | Source: NIH/NCI
April 1, 2020 – March 3, 2025
In collaboration with Drs. Daohong Zhou and Marina Konopleva (MDACC)
Use of BCL-xL Proteolysis Targeting Chimeras to Treat Pancreatic Cancer
Project Number: R01 CA242003 | Source: NIH/NCI
September 1, 2019 – August 31, 2024
In collaboration with Drs. Daohong Zhou and Jose Trevino
Develop BCL-xL Proteolysis Targeting Chimeras as Safer and Better Senolytics
Project Number: R01 AG063801 | Source: NIH/NIA
August 1, 2019 – March 31, 2024
In collaboration with Drs. Daohong Zhou and Jennifer Elisseeff (JHU)
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis (RIPF)
Project Number: R01 CA219836 | Source: NIH/NCI
August 18, 2017 – July 31, 2022
In collaboration with Dr. Daohong Zhou